A Retrospective Study Comparing the Effect of Conventional Coagulation Parameters Vs. Thromboelastography-Guided Blood Product Utilization in Patients With Major Gastrointestinal Bleeding
CONCLUSION: This study revealed that TEG is not superior to conventional coagulation parameters in limiting the volume of blood product transfusion in major GIB patients in ICU settings.PMID:38189039 | PMC:PMC10769601 | DOI:10.14740/jocmr5022 (Source: Clin Med Res)
Source: Clin Med Res - January 8, 2024 Category: Research Authors: Chhabindra Nepal Ojbindra Kc Manisha Koirala Ananta Subedi Rakshya Sharma Srinadh Annangi Suha Jabak Said Chaaban Source Type: research
Organ-specific immune-mediated reactions to polyethylene glycol and polysorbate excipients: three case reports
In this report, we present 3 cases of drug-related AP, AIN and DILI. The first case involved a patient with AP to lacosamide and to the excipient polysorbate 80 in pantoprazole. The second case involved a patient with DILI secondary to polyethylene glycol (PEG) excipients and amoxicillin-clavulanate. In case 3, AIN was considered to be the result of sensitization to excipients. Diagnoses were made using causality algorithms and the LTT. The LTT is a useful tool for helping diagnose drug-related AP and DILI, and it can be used to identify the specific drug or excipient causing the ADR. These cases highlight the importance o...
Source: Frontiers in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Source Type: research
Pantoprazole
(Source: Reactions Weekly)
Source: Reactions Weekly - January 1, 2024 Category: Drugs & Pharmacology Source Type: research
PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes
In this study, we aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of pantoprazole in populations with various CYP2C19 metabolic activities. A comprehensive investigation of previous reports and drug databases was conducted to collect the clinical pharmacogenomic data, physicochemical data, and disposition properties of pantoprazole, and the collected data were used for model establishment. The model was evaluated by comparing the predicted plasma concentration-time profiles and/or pharmacokinetic parameters (AUC and Cmax) with the clinical observation results. The p...
Source: Archives of Pharmacal Research - December 27, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Eunvin Ko Ju Yeon Mo Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes
In this study, we aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of pantoprazole in populations with various CYP2C19 metabolic activities. A comprehensive investigation of previous reports and drug databases was conducted to collect the clinical pharmacogenomic data, physicochemical data, and disposition properties of pantoprazole, and the collected data were used for model establishment. The model was evaluated by comparing the predicted plasma concentration-time profiles and/or pharmacokinetic parameters (AUC and Cmax) with the clinical observation results. The p...
Source: Archives of Pharmacal Research - December 27, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Eunvin Ko Ju Yeon Mo Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study
AbstractPantoprazole decreases the acidity of the tumor microenvironment by inhibiting proton pumps on the cancer cell. This possibly leads to increased sensitivity to cytotoxic therapy. We conducted a phase I/II randomized controlled trial in adult patients with head and neck squamous cell carcinoma (HNSCC) planned for firs t-line palliative chemotherapy. Patients were randomized to chemotherapy + / − intravenous (IV) pantoprazole. The primary endpoint in phase I was to determine the maximum safe dose of intravenous pantoprazole, whereas it was progression-free survival (PFS) in phase II. The dose of IV panto...
Source: Medical Oncology - December 21, 2023 Category: Cancer & Oncology Source Type: research
Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers
ConclusionIn conclusion, we observed an increased midazolam exposure most likely related to pantoprazole. (Source: European Journal of Drug Metabolism and Pharmacokinetics)
Source: European Journal of Drug Metabolism and Pharmacokinetics - December 20, 2023 Category: Drugs & Pharmacology Source Type: research
REVISE: re-evaluating the inhibition of stress erosions in the ICU —statistical analysis plan for a randomized trial
The REVISE (Re-Evaluating the Inhibition of Stress Erosions in the ICU) trial will evaluate the impact of the proton pump inhibitor pantoprazole compared to placebo in invasively ventilated critically ill patient... (Source: Trials)
Source: Trials - December 6, 2023 Category: General Medicine Authors: Diane Heels-Ansdell, Laurent Billot, Lehana Thabane, Waleed Alhazzani, Adam Deane, Gordon Guyatt, Simon Finfer, Fran çois Lauzier, John Myburgh, Paul Young, Yaseen Arabi, John Marshall, Shane English, John Muscedere, Marlies Ostermann, Bala Venkatesh & h Tags: Research Source Type: research
Acid ‐suppressive drugs: A systematic review and network meta‐analysis of their nocturnal acid‐inhibitory effect
ConclusionsThis is the first study to compare the effect of ASDs on inhibiting nocturnal acid breakthrough. Overall, in terms of nocturnal acid-inhibitory effect, vonoprazan and tegoprazan had an advantage against other regimens including H2RAs, isomer PPIs, traditional PPIs, AHB, and new PPIs. Even in some subgroups, such as language classification (English), types of study design (crossover-RCT), age ( ≤40 years), BMI (18.5-24.9 kg/m2), continent (Asia and North America), disease status (health), the duration of therapy (2 weeks), and time of administration (at daytime or at night-time), the nocturnal acid-inhibit...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 5, 2023 Category: Drugs & Pharmacology Authors: Shupeng Zou,
Mengling Ouyang,
Qian Cheng,
Xuan Shi,
Minghui Sun Tags: RESEARCH ARTICLE Source Type: research
69-Year-Old Man With Inflammatory Bowel Disease and Diarrhea
A 69-year-old man presented to the emergency department with 1 week of diarrhea and abdominal pain. Stools were described as loose and nonbloody, occurring 8 to 12 times a day, associated with abdominal cramping, urgency, and nocturnal diarrhea. The patient ’s medical conditions included a 20-year history of left-sided ulcerative colitis (currently in endoscopic remission) treated with tofacitinib 5 mg twice daily and Barrett esophagus treated with pantoprazole 40 mg daily. The patient denied associated fever, weight loss, vomiting, correlation with diet, recent travel, sick contacts, hospitalization, and antibiotic or c...
Source: Mayo Clinic Proceedings - December 1, 2023 Category: Internal Medicine Authors: Christian Karime, Caroline Olson, Razvan Chirila Tags: Residents ’ Clinic Source Type: research
Investigation into the Impact of Proton Pump Inhibitors on Sertraline Transport across the Blood-Brain Barrier
In this study, PPIs were further found to inhibit the mRNA and protein expression of brain BCRP. To sum up, the findings of this study revealed that PPIs could enhance the brain distribution and antidepressant effect of sertraline, which may be attributed to the inhibition of BCRP expression at the BBB by PPIs.PMID:38006986 | DOI:10.1016/j.ejps.2023.106653 (Source: European Journal of Pharmaceutical Sciences)
Source: European Journal of Pharmaceutical Sciences - November 25, 2023 Category: Drugs & Pharmacology Authors: Yumeng Xiao Wenwen Xu Dandan Niu Zhuowei Quan Ling Wang Source Type: research
REVISE: Re-Evaluating the Inhibition of Stress Erosions in the ICU: a randomised trial protocol
The objective of this report is to describe the rationale, methodology, ethics and management of REVISE.
Methods and analysis
REVISE is an international, randomised, concealed, stratified, blinded parallel-group individual patient trial being conducted in ICUs in Canada, Australia, Saudi Arabia, UK, US, Kuwait, Pakistan and Brazil. Patients≥18 years old expected to remain invasively mechanically ventilated beyond the calendar day after enrolment are being randomised to either 40 mg pantoprazole intravenously or an identical placebo daily while mechanically ventilated in the ICU. The primary efficacy outcome is clinical...
Source: BMJ Open - November 15, 2023 Category: General Medicine Authors: Deane, A. M., Alhazzani, W., Guyatt, G., Finfer, S., Marshall, J. C., Myburgh, J., Zytaruk, N., Hardie, M., Saunders, L., Knowles, S., Lauzier, F., Chapman, M. J., English, S., Muscedere, J., Arabi, Y., Ostermann, M., Venkatesh, B., Young, P., Thabane, L. Tags: Open access, Intensive care Source Type: research
pH-Sensitive Adsorption of Gastrointestinal Drugs (Famotidine and Pantoprazole) as pharmaceutical pollutants by Au-Doped@ZIF-90-Glycerol Adsorbent: Insights from Computational Modeling
J. Mater. Chem. A, 2023, Accepted Manuscript DOI: 10.1039/D3TA05221D, PaperNarjes Montazeri, Iman Salahshoori , Parivash Feyzishendi, Fatemeh Sadat Miri, Mehdi Moayed Mohseni, Hossein Ali Khonakdar Pharmaceutical pollutants, such as gastrointestinal drugs, pose a significant environmental concern due to their widespread use and potential adverse effects on ecosystems. Insights obtained from computational simulations yielded a more... The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - J. Mater. Chem. latest articles)
Source: RSC - J. Mater. Chem. latest articles - November 9, 2023 Category: Chemistry Authors: Narjes Montazeri Source Type: research
